Involvement of subthalamic nucleus in the stimulatory effect of Δ9-tetrahydrocannabinol on dopaminergic neurons

Neuroscience

Volumn 151, Issue 3, 2008, Pages 817-823

  Morera Herreras, T ^a   Ruiz Ortega, J A ^a   Gomez Urquijo S ^a   Ugedo, L ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

basal ganglia; cannabinoid; electrophysiology; excitatory amino acids

Indexed keywords

DRONABINOL; EXCITATORY AMINO ACID; IBOTENIC ACID; KYNURENIC ACID; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; MALE; NERVE CELL; NERVE CELL MEMBRANE POTENTIAL; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SINGLE UNIT ACTIVITY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; IBOTENIC ACID; KYNURENIC ACID; MALE; NEURONS; PIPERIDINES; PSYCHOTROPIC DRUGS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TETRAHYDROCANNABINOL;

EID: 38749125491     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.11.016     Document Type: Article

References (53)

1. Benazzouz A., Gao D., Ni Z., and Benabid A.L. High frequency stimulation of the STN influences the activity of dopamine neurons in the rat. Neuroreport 11 (2000) 1593-1596
2. Bilbao G., Ruiz-Ortega J.A., Miguens N., Ulibarri I., Linazasoro G., Gomez-Urquijo S., Garibi J., and Ugedo L. Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: Effects of subthalamotomy and levodopa treatment. Brain Res 1084 1 (2006) 175-184
3. Breivogel C.S., Griffin G., Di Marzo V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60 (2001) 155-163
4. Brotchie J.M. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 3 (2003) 54-61
5. Cheer J.F., Kendall D.A., Mason R., and Marsden C.A. Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum. Neuropharmacology 44 (2003) 633-641
6. Chergui K., Charlety P.J., Akaoka H., Saunier C.F., Brunet J.L., Buda M., Svensson T.H., and Chouvet G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5 (1993) 137-144
7. Christoffersen C.L., and Meltzer L.T. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience 67 (1995) 373-381
8. Consroe P. Brain cannabinoid systems as targets for therapy of neurological disorders. Neurobiol Dis 5 (1998) 534-551
9. Diana M., Melis M., and Gessa G.L. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10 (1998) 2825-2830
10. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., and Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75 (2000) 2434-2444
11. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., and Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14 (2000) 1432-1438
12. Fernandez-Espejo E., Caraballo I., Rodriguez de Fonseca F., Ferrer B., Banoua F.E., Flores J.A., and Galan-Rodriguez B. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology 29 (2004) 1134-1142
13. French E.D. Delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226 (1997) 159-162
14. French E.D., Dillon K., and Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8 (1997) 649-652
15. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83 (2003) 1017-1066
16. Fride E., Foox A., Rosenberg E., Faigenboim M., Cohen V., Barda L., Blau H., and Mechoulam R. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 461 (2003) 27-34
17. Gerdeman G., and Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85 (2001) 468-471
18. Gerfen C.R., and Wilson C.J. The basal ganglia. In: Swanson L.W., Bjorklund A., and Hokfelt T. (Eds). Handbook of chemical neuroanatomy, Vol. 12, Integrated systems of the CNS, Pt III (1996), Elsevier, Amsterdam 371-468
19. Gessa G.L., Melis M., Muntoni A.L., and Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341 (1998) 39-44
20. Grace A.A., and Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience 10 (1983) 301-315
21. Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4 (1984) 2877-2890
22. Grenhoff J., Ugedo L., and Svensson T.H. Firing patterns of midbrain dopamine neurons: differences between A9 and A10 cells. Acta Physiol Scand 134 (1988) 127-132
23. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agro A., and Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22 (2002) 6900-6907
24. Hamani C., Saint-Cyr J.A., Fraser J., Kaplitt M., and Lozano A.M. The subthalamic nucleus in the context of movement disorders. Brain 127 (2004) 4-20
25. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990) 1932-1936
26. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
27. Julian M.D., Martin A.B., Cuellar B., Rodriguez De Fonseca F., Navarro M., Moratalla R., and Garcia-Segura L.M. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119 (2003) 309-318
28. Kita H., and Kitai S.T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 260 (1987) 435-452
29. Kosinski C.M., Standaert D.G., Testa C.M., Penney Jr. J.B., and Young A.B. Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat. Neuroscience 86 (1998) 783-798
30. Mailleux P., Parmentier M., and Vanderhaeghen J.J. Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett 143 (1992) 200-204
31. Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., and Freund T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137 (2006) 337-361
32. Mechoulam R., Shani A., Edery H., and Grunfeld Y. Chemical basis of hashish activity. Science 169 (1970) 611-612
33. Melis M., Gessa G.L., and Diana M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 24 (2000) 993-1006
34. Miller A.S., Sañudo-Peña M.C., and Walker J.M. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus. Brain Res 793 (1998) 7-11
35. Obeso J.A., Rodriguez-Oroz M.C., Lanciego J.L., and Rodriguez-Diaz M. How does Parkinson's disease begin? The role of compensatory mechanisms. Trends Neurosci 27 (2004) 125-127
36. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd ed (1986), Academic Press, Orlando
37. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 Suppl 1 (2006) S163-S171
38. Pistis M., Perra S., Pillolla G., Melis M., Gessa G.L., and Muntoni A.L. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 46 (2004) 115-125
39. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 (1994) 240-244
40. Rinvik E., and Ottersen O.P. Terminals of subthalamonigral fibres are enriched with glutamate-like immunoreactivity: an electron microscopic, immunogold analysis in the cat. J Chem Neuroanat 6 (1993) 19-30
41. Rodriguez de Fonseca F., Del Arco I., Martin-Calderon J.L., Gorriti M.A., and Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5 (1998) 483-501
42. Sañudo-Peña M.C., Force M., Tsou K., Miller A.S., and Walker J.M. Effects of intrastriatal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Synapse 30 (1998) 221-226
43. Sañudo-Peña M.C., Patrick S.L., Khen S., Patrick R.L., Tsou K., and Walker J.M. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci Lett 248 (1998) 171-174
44. Sañudo-Peña M.C., Patrick S.L., Patrick R.L., and Walker J.M. Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci Lett 206 (1996) 21-24
45. Sañudo-Peña M.C., and Walker J.M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 77 (1997) 1635-1638
46. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., and Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001) 2108-2111
47. Silverdale M.A., McGuire S., McInnes A., Crossman A.R., and Brotchie J.M. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 169 (2001) 400-406
48. Szabo B., Muller T., and Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 73 (1999) 1084-1089
49. Szabo B., and Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol 168 (2005) 327-365
50. Szabo B., Wallmichrath I., Mathonia P., and Pfreundtner C. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97 (2000) 89-97
51. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
52. Tung C.S., Grenhoff J., and Svensson T.H. Kynurenate blocks the acute effects of haloperidol on midbrain dopamine neurons recorded in vivo. J Neural Transm Gen Sect 84 (1991) 53-64
53. Wallmichrath I., and Szabo B. Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) 326-334